Arrowhead Research | ARWR - Current Liabilities


Arrowhead Research reported $347.42M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Anika Therapeutics USD 21.91M 2.82M Dec/2025
Arrowhead Research USD 347.42M 151.94M Dec/2025
Heron Therapeutics USD 96.1M 6.39M Dec/2025
Incyte USD 1.52B 176.44M Dec/2025
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
Ligand Pharmaceuticals USD 37.45M 6.91M Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Moderna USD 1.99B 306M Dec/2025
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Novartis USD 27.28B 4.72B Dec/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
TG Therapeutics USD 153.76M 3.05M Dec/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025
Xencor USD 95.91M 9.42M Dec/2025